Publications ORBi OA
Bookmark and Share    
Full Text
Peer Reviewed
See detailA role for the Clostridium perfringens beta 2 toxin in bovine enterotoxaemia?
Manteca, Christophe; Daube, Georges ULg; Jauniaux, Thierry ULg et al

in Veterinary Microbiology (2002), 86(3), 191-202

Non-enterotoxigenic type A Clostridium perfringens are associated with bovine enterotoxaemia, but the alpha toxin is not regarded as responsible for the production of typical lesions of necrotic and ... [more ▼]

Non-enterotoxigenic type A Clostridium perfringens are associated with bovine enterotoxaemia, but the alpha toxin is not regarded as responsible for the production of typical lesions of necrotic and haemorrhagic enteritis. The purpose of this study was to investigate the putative role of the more recently described beta2 toxin. Seven hundred and fourteen non-enterotoxigenic type A C. perfringens isolated from 133 calves with lesions of enterotoxaemia and high clostridial cell counts (study population) and 386 isolated from a control population of 87 calves were tested by a colony hybridisation assay for the beta2 toxin. Two hundred and eighteen (31%) C perfringens isolated from 83 calves (62%) of the study population and 113 (29%) C. perfringens isolated from 51 calves (59%) of the control population tested positive with the beta2 probe. Pure and mixed cultures of four C perfringens (one alpha+beta2+, one alpha+enterotoxin-1 and two alpha+) were tested in the ligated loop assay in one calf. Macroscopic haemorrhages of the intestinal wall, necrosis and haemorrhages of the intestinal content, and microscopic lesions of necrosis and polymorphonuclear and mononuclear cell infiltration of the intestinal villi were more pronounced in loops inoculated with the a and beta2-toxigenic C. perfringens isolate. These results suggest in vivo synergistic role of the alpha and beta2 toxins in the production of necrotic and haemorrhagic lesions of the small intestine in cases of bovine enterotoxaemia. However, isolation of beta2-toxigenic C. perfringens does not confirm the clinical diagnosis of bovine enterotoxaemia and a clostridial cell counts must still be performed. (C) 2002 Elsevier Science B.V. All rights reserved. [less ▲]

Detailed reference viewed: 131 (25 ULg)
Full Text
Peer Reviewed
See detailAdhesion of synchronized human hematopoietic progenitor cells to fibronectin and vascular cell adhesion molecule-1 fluctuates reversibly during cell cycle transit in ex vivo culture.
Huygen, Sandra; Giet, Olivier ULg; Artisien, Vincent et al

in Blood (2002), 100(8), 2744-52

Ex vivo expansion of hematopoietic stem/progenitor cells may result in defective engraftment. Human cord blood CD34(+) progenitor cells were synchronized and assayed for adhesion and migration onto ... [more ▼]

Ex vivo expansion of hematopoietic stem/progenitor cells may result in defective engraftment. Human cord blood CD34(+) progenitor cells were synchronized and assayed for adhesion and migration onto fibronectin (Fn) and vascular cell adhesion molecule-1 (VCAM-1) at different stages of a first cell cycle executed ex vivo. During S phase transit, adhesion to Fn was transiently increased while binding to VCAM-1 was reversibly decreased, after which adhesion to both ligands returned to baseline levels with cell cycle completion. Transmigration across Fn and VCAM-1 decreased irreversibly during S phase progression. The function of alpha4 and alpha5 integrins was assessed with specific neutralizing antibodies. In uncultured CD34(+) cells and long-term culture-initiating cells (LTC-ICs), both adhesion and migration on Fn were inhibited by anti-alpha4 but not by anti-alpha5 antibodies. In mitotically activated CD34(+) cells and LTC-ICs, adhesion and migration on Fn were mainly dependent on alpha5 integrin and to a lesser extent on alpha4 integrin. Changes in integrin function were not dependent on parallel modulation of integrin expression. In conclusion, Fn and VCAM-1 binding of progenitor cells fluctuates reversibly during cell cycle transit ex vivo. In addition, our data show that mitogenic activation induces a shift from a dominant alpha4 to a preferential alpha5 integrin-dependent interaction with Fn. [less ▲]

Detailed reference viewed: 36 (3 ULg)
Full Text
Peer Reviewed
See detailIncreased binding and defective migration across fibronectin of cycling hematopoietic progenitor cells.
Giet, Olivier ULg; Van Bockstaele, Dirk R; Di Stefano, Ivano et al

in Blood (2002), 99(6), 2023-31

Engraftment of hematopoietic progenitor cells has been shown to decrease during cell cycle transit. We studied cell cycle-associated changes in adhesion and migration of mitotically activated cord blood ... [more ▼]

Engraftment of hematopoietic progenitor cells has been shown to decrease during cell cycle transit. We studied cell cycle-associated changes in adhesion and migration of mitotically activated cord blood CD34+ cells. Migration toward medium conditioned by the stromal-derived factor-1-producing cell line MS-5 was studied in bovine serum albumin- and fibronectin (Fn)-coated transwells. Migration was reduced in cycling CD34+ cells and long-term culture-initiating cells (LTC-ICs) compared with their noncycling counterparts across Fn but not across bovine serum albumin. Conversely, Fn binding was higher in cycling CD34+ cells and LTC-ICs compared with noncycling progenitor cells, while adhesion of both subsets to bovine serum albumin was undetectable. The contribution of alpha4 and alpha5 integrins in mediating adhesion and migration of activated CD34+ cells onto Fn was analyzed by neutralization experiments. While alpha4-mediated Fn binding decreased during G(2)/M, alpha5 integrin-mediated adhesion increased during transit from G(0)/G(1) to S and G(2)/M phases. As for migration, the contribution of alpha4 integrin was similar in all phases, whereas alpha5-directed migration was lower in G(2)/M compared with G(0)/G(1) and S phases. Defective migration of cycling CD34+ cells was not due to differences in alpha5 integrin expression. In conclusion, chemotaxis across Fn is less efficient in cycling progenitor cells in correlation with an increased Fn binding capacity. In addition, alpha4 and alpha5 integrin functions are independently modulated during cell cycle transit. [less ▲]

Detailed reference viewed: 105 (2 ULg)
Full Text
See detailEvidence For a Self-Enrichment Process in Galactic Halo Globular Clusters
Parmentier, G.; Jehin, Emmanuel ULg; Magain, Pierre ULg et al

in Grebel, E.; Bradner, W. (Eds.) Modes of Star Formation and the Origin of Field Populations (2002)

Not Available

Detailed reference viewed: 9 (4 ULg)
Full Text
See detailMetallicity Gradients in Globular Cluster Systems : the Trace of a Self-Enrichment Process ?
Parmentier, G.; Magain, Pierre ULg; Noels-Grötsch, Arlette ULg et al

in Geisler, E. K.; Grebel, E.; Minniti, D. (Eds.) Extragalactic Star Clusters (2002)

We have developed a model of globular cluster self-enrichment, based on the ability of the globular cluster gaseous progenitors to retain the ejecta of a first generation of Type II Supernovae. The key ... [more ▼]

We have developed a model of globular cluster self-enrichment, based on the ability of the globular cluster gaseous progenitors to retain the ejecta of a first generation of Type II Supernovae. The key point is that this ability depends on the pressure exerted on the progenitor cloud by the surrounding protogalactic medium and therefore on the location of the cloud in the protogalaxy. The model is able to explain the galactic halo metallicities and the metallicity gradient of the Old Halo which is thought to be the genuine galactic globular cluster system. The possibility that metallicity gradients are a common property of extragalactic globular cluster systems is also presented. [less ▲]

Detailed reference viewed: 17 (1 ULg)
Full Text
Peer Reviewed
See detailSerum vitamin E concentrations in a group of horses, with a high incidence of equine motor neurone disease
Delguste, Catherine ULg; de Moffarts, Brieuc; Sandersen, Charlotte ULg et al

in Pflügers Archiv : European Journal of Physiology (2002), 444(1-2), 3

Detailed reference viewed: 21 (5 ULg)
Full Text
Peer Reviewed
See detailSpeed of sound measurements in the evaluation of bone properties in Holstein
Sandersen, Charlotte ULg; Guyot, Hugues ULg; Vandeputte, Sébastien ULg et al

in Proceedings of the XXII World Buiatrics Congress (2002)

Detailed reference viewed: 6 (2 ULg)
Full Text
Peer Reviewed
See detailThe Disulphide Mapping, Folding and Characterisation of Recombinant Ber e 1, an Allergenic Protein, and SFA8, Two Sulphur-rich 2 S Plant Albumins
Alcocer, Marcos; Murtagh, G. J.; Bailey, Kevin et al

in Journal of Molecular Biology (2002), 324

We have cloned and expressed genes encoding the allergenic brazil nut 2 S albumin (Ber e 1) and the sunflower albumin 8 (SFA8) in the methylotrophic yeast Pichia pastoris. We show that both proteins were ... [more ▼]

We have cloned and expressed genes encoding the allergenic brazil nut 2 S albumin (Ber e 1) and the sunflower albumin 8 (SFA8) in the methylotrophic yeast Pichia pastoris. We show that both proteins were secreted at high levels and that the purified proteins were properly folded. We also showed that Ber e 1 is glycosylated during secretion and that the glycan does not interfere with the folding or immunoreactivity. The disulphide map of the Ber e 1 protein was experimentally established and is in agreement with the conserved disulphide structure of other members of the 2 S albumin family. A model three-dimensional structure of the allergen was generated. During the expression studies and through mutation we have also shown that alteration of the sequences around the Kex2 endoproteolytic processing site in the expressed fusion protein can compromise the secretion by targeting part of the protein for possible degradation. The secreted production of these properly folded sulphurrich plant albumins presents an opportunity to delineate the attributes that make an allergen and to facilitate the diagnosis and therapy of type I allergy. [less ▲]

Detailed reference viewed: 18 (2 ULg)
Full Text
Peer Reviewed
See detailL'organisation au regard de l'esthétique
Servais, Christine ULg; Heller, Thomas

in Recherches en Communication (2002), 17

Detailed reference viewed: 32 (6 ULg)
Full Text
Peer Reviewed
See detailL'etude clinique du mois. L'etude PROSPER (PROspective study of pravastatin in the elderly at risk).
Kulbertus, Henri ULg; Scheen, André ULg

in Revue Médicale de Liège (2002), 57(12), 809-13

Statins reduce coronary and cerebrovascular mortality and morbidity in middle-aged individuals. Until recently, their efficacy and safety in elderly people had not yet been firmly established. PROSPER was ... [more ▼]

Statins reduce coronary and cerebrovascular mortality and morbidity in middle-aged individuals. Until recently, their efficacy and safety in elderly people had not yet been firmly established. PROSPER was a controlled, randomised study involving 2,804 men and 3,000 women aged 70-82, with a history of, or risk factors for cardiovascular disease. Their baseline cholesterol level was 135-350 mg/dl; they were randomised to either 40 mg pravastatin per day, or matching placebo. Average follow-up was 3.2 years. The primary endpoint was a composite of coronary death, non-fatal myocardial infarction, and fatal or non-fatal stroke. Pravastatin lowered LDL-cholesterol (-34%), and reduced the incidence of the primary endpoint (-15%; CI 95%: 3-26%; p = 0.014). Coronary death and non-fatal myocardial infarction risk was also reduced (-19%; p = 0.006), and mortality from coronary disease fell by 24% (p = 0.043). The risk for stroke, however, was unaffected (p = 0.8), whereas the incidence of transient ischemic attacks was reduced by 25%, which was (marginally) insignificant (p = 0.051). Pravastatin had no effect on cognitive functions or incapacity. New cancers were more frequent amongst pravastatin-treated individuals (+25%; p = 0.020). However incorporation of this new data in a meta-analysis of all pravastatin and all statin trials revealed no overall increase of cancer risk. [less ▲]

Detailed reference viewed: 114 (0 ULg)
Full Text
Peer Reviewed
See detailActualites therapeutiques 2002 (1).
Scheen, André ULg

in Revue Médicale de Liège (2002), 57(11), 719-31

The most important drugs registered and/or launched in Belgium during the last year in the various disciplines of internal medicine will be briefly described. The main characteristics of each molecule and ... [more ▼]

The most important drugs registered and/or launched in Belgium during the last year in the various disciplines of internal medicine will be briefly described. The main characteristics of each molecule and its modalities of appropriate use in clinical practice will be emphasized. For all these molecules, both the efficacy and tolerance have been proven in randomised clinical trials according to the rules of Evidence-Based Medicine. [less ▲]

Detailed reference viewed: 63 (0 ULg)
Full Text
Peer Reviewed
See detailInfo-congres. Essai de prevention du diabete de type 1 par le nicotinamide: les lecons positives d'un essai clinique negatif (ENDIT).
Philips, Jean-Christophe ULg; Scheen, André ULg

in Revue Médicale de Liège (2002), 57(10), 672-5

ENDIT ("European Nicotinamide Diabetes Intervention Trial") is a large placebo-controlled randomised clinical trial that aimed at studying the efficacy of nicotinamide in the prevention of type 1 diabetes ... [more ▼]

ENDIT ("European Nicotinamide Diabetes Intervention Trial") is a large placebo-controlled randomised clinical trial that aimed at studying the efficacy of nicotinamide in the prevention of type 1 diabetes mellitus among first-degree relatives of type 1 diabetic patients with positive islet cell antibodies (ICA). The results presented at the last congress of the European Association for the Study of Diabetes (EASD) in Budapest do not evidence any significant difference in the risk of developing overt diabetes mellitus in the patients treated with nicotinamide (n = 274) as compared to those receiving placebo (n = 275) after 5 years of follow-up. Despite these negative results, positive lessons could be drawn from ENDIT: 1) the feasibility of a large long-standing multicentre European trial in a difficult research area; 2) the importance of large randomised controlled clinical trials to bring the evidence requested by "Evidence-Based Medicine"; 3) the predictive value of various risk markers to progress toward type 1 diabetes in first-degree relatives, especially the number of positive auto-antibodies; and 4) the urgent need to continue intensive research in this important field of preventive medicine. [less ▲]

Detailed reference viewed: 40 (0 ULg)
Full Text
Peer Reviewed
See detailInfo-congres. Prevention du diabete de type 2 chez le sujet obese: premiers resultats avec l'orlistat dans l'etude XENDOS.
Scheen, André ULg

in Revue Médicale de Liège (2002), 57(9), 617-21

The results of the XENDOS study were presented by Professor Lars Sjostrom (Gothenburg, Sweden), on August 26, 2002, at the 9th International Congress on Obesity in Sao Paulo, Brazil. XENDOS (XENical in ... [more ▼]

The results of the XENDOS study were presented by Professor Lars Sjostrom (Gothenburg, Sweden), on August 26, 2002, at the 9th International Congress on Obesity in Sao Paulo, Brazil. XENDOS (XENical in the prevention of Diabetes in Obese Subjects) is a multicentre, randomised, double-blind, placebo-controlled, parallel-group prospective study performed in Sweden over a period of 4 years. The aim of XENDOS was to investigate the use of a weight loss agent (orlistat, Xenical) compared with lifestyle changes for the prevention of type 2 diabetes in obese patients (body mass index > or = 30 kg/m2). Weight loss was greater in the orlistat group (-6.9 kg; n = 1.640) than in the placebo group (-4.1 kg; n = 1.637; p < 0.001). Such a difference in weight reduction was sufficient to significantly reduce the cumulative incidence of type 2 diabetes (6.2% versus 9.0%; p = 0.0032; relative risk reduction of 37.3%). The difference was especially remarkable in obese patients with impaired glucose tolerance (21% of the cohort), with a reduction of conversion to diabetes from 28.8% in the placebo group to 18.8% in the orlistat group (p < 0.005) and a number needed to treat to avoid one event of 11 only. Significant and sustained reductions in cardiovascular risk factors such as arterial blood pressure and lipid levels were also observed in the orlistat group as compared to the placebo group. XENDOS is the first study demonstrating that an antiobesity agent, like orlistat, is able to reduce the progression to diabetes in obese subjects as compared with lifestyle changes alone. [less ▲]

Detailed reference viewed: 110 (0 ULg)
Full Text
Peer Reviewed
See detailL'etude clinique du mois. La MRC/BHF Heart Protection Study.
Kulbertus, Henri ULg; Scheen, André ULg

in Revue Médicale de Liège (2002), 57(9), 613-6

20,536 adults (15,454 men and 5,082 women, aged 40-80 years) with coronary heart disease, other occlusive arterial disease or diabetes mellitus were randomly allocated to receive 40 mg simvastatin daily ... [more ▼]

20,536 adults (15,454 men and 5,082 women, aged 40-80 years) with coronary heart disease, other occlusive arterial disease or diabetes mellitus were randomly allocated to receive 40 mg simvastatin daily or matching placebo. In addition to being randomized to compare simvastatin vs placebo, all patients were also randomized to compare antioxidant vitamin supplementation (vitamin E 600 mg/day, vitamin C 250 mg/day and betacarotene 20 mg/day) vs placebo in a "2 x 2 factorial" design. Duration of the study was 5 years. All-cause mortality was significantly reduced among patients allocated to simvastatin (-12.3%) due to a highly significant (-18%) reduction in the coronary death rate, a marginally significant reduction in other vascular deaths and a non-significant reduction in non-vascular deaths. There were highly significant reductions (of about one-quarter) in the first event rate for non-fatal myocardial infarction and coronary death (combined), for non-fatal and fatal stroke and for coronary or non-coronary revascularization. The beneficial effect of simvastatin was seen in all sub-categories which were studied and, particularly: women vs men; patients aged > 70 years vs those aged < 70 years; patients with LDL cholesterol < vs > 116 mg/dl, or total cholesterol < vs > 193 mg/dl. The treatment was well tolerated and the annual risk of myopathy was 0.01%. All comparisons between antioxidant vitamin supplementation and placebo failed to reveal any difference in favour or against the supplementation which was otherwise well tolerated. These important results and their implications will be briefly discussed. [less ▲]

Detailed reference viewed: 113 (1 ULg)
Full Text
Peer Reviewed
See detailL'etude clinique du mois. L'etude LIPS: prevention par la fluvastatine des accidents cardiaques apres angioplastie coronaire percutanee.
Scheen, André ULg

in Revue Médicale de Liège (2002), 57(7), 479-82

The prospective placebo-controlled LIPS study ("Lescol Intervention Prevention Study") demonstrated a significant cardiovascular protection by fluvastatin in patients with coronary artery disease (stable ... [more ▼]

The prospective placebo-controlled LIPS study ("Lescol Intervention Prevention Study") demonstrated a significant cardiovascular protection by fluvastatin in patients with coronary artery disease (stable or unstable angina, silent ischemia), without major hypercholesterolaemia (135-270 mg/dl) following successful completion of their first percutaneous coronary intervention. When compared to the placebo group (n = 833), the fluvastatin group (n = 844) showed a relative risk reduction by 22% (relative risk: 0.78; 95% confidence interval: 0.64-0.95; p = 0.01) of major adverse cardiac events after a median time of follow-up of 3.9 years. This effect is observed independently of baseline total cholesterol, of the presence of diabetes mellitus or the existence of multivessel disease. These results suggest that fluvastatin may favorably influence the restenosis process after percutaneous coronary intervention, even in the absence of severe hypercholesterolaemia. [less ▲]

Detailed reference viewed: 26 (0 ULg)
Full Text
Peer Reviewed
See detailPrevention de l'apparition du diabete de type 2 par l'inhibition du systeme renine-angiotensine.
Scheen, André ULg

in Revue Médicale de Liège (2002), 57(7), 449-52

Type 2 diabetes mellitus and arterial hypertension are part of the insulin resistance syndrome. Besides a metabolic component, insulin resistance has also an haemodynamic component, especially in relation ... [more ▼]

Type 2 diabetes mellitus and arterial hypertension are part of the insulin resistance syndrome. Besides a metabolic component, insulin resistance has also an haemodynamic component, especially in relation with an endothelial dysfunction. Some studies suggested that inhibitors of angiotensin converting enzyme can improve insulin sensitivity. Interestingly enough, three clinical trials recently reported concordant results showing that the inhibition of the renin-angiotensin system significantly reduces the risk of developing type 2 diabetes in patients at high risk of vascular complications, essentially with hypertension: the CAPPP trial with captopril (-14%, p = 0.39), the HOPE study with ramipril (-34%, p < 0.001) and the LIFE study with losartan (-25%, p < 0.001). However, these observations could be criticized because such a protective effect was only considered as a secondary endpoint in these studies. Two large prospective, controlled, randomized, double-blind trials are ongoing to specifically confirm this interesting hypothesis, one with ramipril and the other with valsartan. [less ▲]

Detailed reference viewed: 98 (0 ULg)
Full Text
Peer Reviewed
See detailL'etude clinique du mois. Essais de preservation des cellules B a la phase initiale du diabete de type 1: resultats negatifs avec l'insuline retard, mais prometteurs avec un anticorps monoclonal anti-CD3.
Philips, Jean-Christophe ULg; Scheen, André ULg

in Revue Médicale de Liège (2002), 57(6), 413-7

Type 1 diabetes is an autoimmune disease leading to a progressive exhaustion of the insulin secretion and a destruction of the B-cells. Attempts of preservation of insulin-producing B-cells can be ... [more ▼]

Type 1 diabetes is an autoimmune disease leading to a progressive exhaustion of the insulin secretion and a destruction of the B-cells. Attempts of preservation of insulin-producing B-cells can be performed at an early, most often silent, stage of the disease in well-selected at high risk subjects or during the period immediately following the clinical diagnosis based upon classical signs of hyperglycaemia. In the "Diabetes Prevention Trial-Type 1", the prophylactic subcutaneous administration of low-dose ultralente insulin was not able to prevent the development of type 1 diabetes nor to preserve residual insulin secretion in young relatives at very high-risk of diabetes, selected upon genetic, immunological and metabolic criteria. In contrast, a pilot randomized trial shows that a treatment with a nonactivating humanized monoclonal antibody against CD3 mitigates the deterioration in insulin production and improves metabolic control, with lower dose of exogenous insulin, during the first year of type 1 diabetes mellitus in 9 out of 12 treated patients. Besides a better understanding of the natural history of the disease, these clinical trials open new perspectives for prevention of type 1 diabetes mellitus, currently assessed by the Belgian Diabetes Registry. [less ▲]

Detailed reference viewed: 92 (1 ULg)
Full Text
Peer Reviewed
See detailPieges et conseils a propos de l'utilisation des antidiabetiques oraux conventionnels.
Scheen, André ULg

in Revue Médicale de Liège (2002), 57(5), 352-6

The main pitfalls regarding the use of sulphonylureas and metformin in type 2 diabetic patients are described and illustrated by a clinical case. Advices are given in order to avoid the occurrence of ... [more ▼]

The main pitfalls regarding the use of sulphonylureas and metformin in type 2 diabetic patients are described and illustrated by a clinical case. Advices are given in order to avoid the occurrence of severe hypoglycaemic episodes with sulphonylureas and to minimise the risk of lactic acidosis with metformin. These drugs, when used appropriately with respect of contra-indications, have an excellent safety profile and remain the basis of the treatment of type 2 diabetes. [less ▲]

Detailed reference viewed: 128 (0 ULg)
Full Text
Peer Reviewed
See detailUn diabete peut en cacher un autre.
Scheen, André ULg

in Revue Médicale de Liège (2002), 57(5), 267-9

The abrupt interruption of insulin therapy in a severely obese diabetic woman submitted to a protein-sparing modified fast in a metabolic ward led to a severe ketoacidosis. This complication occurred ... [more ▼]

The abrupt interruption of insulin therapy in a severely obese diabetic woman submitted to a protein-sparing modified fast in a metabolic ward led to a severe ketoacidosis. This complication occurred because the patient had type 1 rather than type 2 diabetes, and the diagnosis of ketoacidosis was delayed because of confusion between ketonuria resulting from insulin deprivation and ketonuria associated with carbohydrate and energy restriction. This case report illustrates the danger of accepting an apparently obvious diagnosis which might be in fact erroneous. More particularly, it points out the importance of a correct differential diagnosis between C-peptide positive insulin-requiring type 2 diabetes and C-peptide negative (insulin-dependent) type 1 diabetes. [less ▲]

Detailed reference viewed: 28 (0 ULg)